Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln (OTHER 106410809-2124721) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 10, 2026 , from http://ppman.hank.ai/transparency/procedure/106410809-2124721/by-state?code_type=OTHER
“00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln (OTHER 106410809-2124721) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/106410809-2124721/by-state?code_type=OTHER. Accessed
November 10, 2026 .
“00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln (OTHER 106410809-2124721) by State,” HANK Price Transparency ,
accessed November 10, 2026 ,
http://ppman.hank.ai/transparency/procedure/106410809-2124721/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
106410809-2124721 — 00310-3040-00 - Anifrolumab Fnia 300 Mg/2 Ml Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$312,656
National median
$235,780 – $363,857
IQR (p25 – p75)
2
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 106410809-2124721 (OTHER), with interquartile range
State Median p25 p75
IN $312,656 $235,780 $363,857